German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

15. Januar 2018

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.